Literature DB >> 16896870

Current strategies of chemotherapy in osteosarcoma.

Dorothe Carrle1, Stefan S Bielack.   

Abstract

Osteosarcoma, the most common type of primary malignant tumour that develops in bone, can be classified into several different sub-types. While the majority of osteosarcomas are highly malignant, there are some low-grade variants. Since the introduction of chemotherapy into the multi-modal treatment regimen of high-grade osteosarcoma, its prognosis has impressively improved, with long-term survival being achieved in two-thirds of all patients. This review summarises current chemotherapeutic treatment strategies in classical osteosarcoma and also addresses the indication for chemotherapy in more unusual types and variants. It emphasises the need for treatment in specialised centres and within prospective, multi-institutional trials, amongst which EURAMOS1 and EURO-B.O.S.S are currently active in many European countries.

Entities:  

Mesh:

Year:  2006        PMID: 16896870      PMCID: PMC3172747          DOI: 10.1007/s00264-006-0192-x

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  30 in total

Review 1.  Limb sparing surgery for pediatric musculoskeletal tumors.

Authors:  Harish S Hosalkar; John P Dormans
Journal:  Pediatr Blood Cancer       Date:  2004-04       Impact factor: 3.167

2.  Periosteal osteosarcoma--a European review of outcome.

Authors:  Robert J Grimer; Stefan Bielack; Silke Flege; Stephen R Cannon; Gunnar Foleras; Ivan Andreeff; Todor Sokolov; Antonie Taminiau; Martin Dominkus; Mikel San-Julian; Yehuda Kollender; Georg Gosheger
Journal:  Eur J Cancer       Date:  2005-11-14       Impact factor: 9.162

3.  Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?

Authors:  Norman Jaffe; Humberto Carrasco; Kevin Raymond; Alberto Ayala; Farzin Eftekhari
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

4.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  Extraosseous osteosarcoma: response to treatment and long-term outcome.

Authors:  Syed A Ahmad; Shreyaskumar R Patel; Matthew T Ballo; Treneth P Baker; Alan W Yasko; Xuemei Wang; Barry W Feig; Kelly K Hunt; Patrick P Lin; Kristen L Weber; Lei L Chen; Gunar K Zagars; Raphael E Pollock; Robert S Benjamin; Peter W T Pisters
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

6.  Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group.

Authors:  S S Bielack; B Kempf-Bielack; U Heise; D Schwenzer; K Winkler
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

7.  Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.

Authors:  Stefano Ferrari; Antonio Briccoli; Mario Mercuri; Franco Bertoni; Piero Picci; Amelia Tienghi; Adalberto Brach Del Prever; Franca Fagioli; Alessandro Comandone; Gaetano Bacci
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

8.  High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.

Authors:  G Bacci; S Ferrari; A Longhi; P Picci; M Mercuri; T A Alvegard; G Saeter; D Donati; M Manfrini; S Lari; A Briccoli; C Forni
Journal:  J Chemother       Date:  2002-04       Impact factor: 1.714

9.  Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

Authors:  Allen M Goorin; Douglas J Schwartzentruber; Meenakshi Devidas; Mark C Gebhardt; Alberto G Ayala; Michael B Harris; Lee J Helman; Holcombe E Grier; Michael P Link
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

10.  Osteosarcoma over the age of forty.

Authors:  R J Grimer; S R Cannon; A M Taminiau; S Bielack; B Kempf-Bielack; R Windhager; M Dominkus; G Saeter; H Bauer; I Meller; M Szendroi; G Folleras; M San-Julian; J van der Eijken
Journal:  Eur J Cancer       Date:  2003-01       Impact factor: 9.162

View more
  78 in total

1.  Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

Authors:  P M Anderson; P Meyers; E Kleinerman; K Venkatakrishnan; D P Hughes; C Herzog; W Huh; R Sutphin; Y M Vyas; V Shen; A Warwick; N Yeager; C Oliva; B Wang; Y Liu; A Chou
Journal:  Pediatr Blood Cancer       Date:  2013-08-31       Impact factor: 3.167

2.  What sports activity levels are achieved in patients with modular tumor endoprostheses of osteosarcoma about the knee?

Authors:  Nikolaus W Lang; Gerhard M Hobusch; Philipp T Funovics; Reinhard Windhager; Jochen G Hofstaetter
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

3.  Best one hundred papers of International Orthopaedics: a bibliometric analysis.

Authors:  Andreas F Mavrogenis; Panayiotis D Megaloikonomos; Georgios N Panagopoulos; Cyril Mauffrey; Andrew Quaile; Marius M Scarlat
Journal:  Int Orthop       Date:  2017-01-04       Impact factor: 3.075

4.  Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma.

Authors:  Ulrike Michaela Pirker-Frühauf; Jörg Friesenbichler; Ernst-Christian Urban; Barbara Obermayer-Pietsch; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2012-07-18       Impact factor: 4.176

5.  Survival analysis of patients with metastatic osteosarcoma: a Surveillance, Epidemiology, and End Results population-based study.

Authors:  Kehan Song; Jian Song; Kaiyuan Lin; Feiyan Chen; Xiaosheng Ma; Jianyuan Jiang; Feng Li
Journal:  Int Orthop       Date:  2019-05-24       Impact factor: 3.075

6.  Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma: A National Cancer Database Study.

Authors:  Daniel R Evans; Alexander L Lazarides; Mark M Cullen; Julia D Visgauss; Jason A Somarelli; Dan G Blazer; Brian E Brigman; William C Eward
Journal:  Ann Surg Oncol       Date:  2021-05-20       Impact factor: 5.344

7.  Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years.

Authors:  Marton König; Terje A Osnes; Ingvild Lobmaier; Bodil Bjerkehagen; Øyvind S Bruland; Kirsten Sundby Hall; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2016-11-17       Impact factor: 3.042

8.  The relation of tumour necrosis and survival in patients with osteosarcoma.

Authors:  Xin Li; Adedayo O Ashana; Vincent M Moretti; Richard D Lackman
Journal:  Int Orthop       Date:  2011-02-26       Impact factor: 3.075

9.  Upregulation of lncRNA HNF1A-AS1 promotes cell proliferation and metastasis in osteosarcoma through activation of the Wnt/β-catenin signaling pathway.

Authors:  Hongxing Zhao; Wengen Hou; Jingang Tao; Yilei Zhao; Guang Wan; Chao Ma; Haibin Xu
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

10.  Paley's multiplier method does not accurately predict adult height in children with bone sarcoma.

Authors:  Magdalena Maria Gilg; Christine Wibmer; Dimosthenis Andreou; Alexander Avian; Petra Sovinz; Werner Maurer-Ertl; Per-Ulf Tunn; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2014-04-29       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.